`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner
`
`v.
`
`POZEN INC. and HORIZON PHARMA USA, INC.
`Patent Owners
`
`
`
`Case No. IPR2018-01995
`Patent No. 9,220,698
`
`
`
`
`DECLARATION OF JONATHAN G. GRAVES IN SUPPORT OF MOTION
`TO APPEAR PRO HAC VICE ON BEHALF OF PATENT OWNER
`HORIZON PHARMA USA, INC.
`
`HORIZON'S EXHIBIT 2008
`Page 1 of 5
`
`
`
`
`
`I, Jonathan G. Graves, do hereby declare:
`
`1.
`
`I am a partner in the law firm Cooley LLP. Lead counsel is Thomas A.
`
`Blinka, who is also a partner in the law firm Cooley LLP. Mr. Blinka is registered
`
`to practice before the United States Patent and Trademark Office and holds
`
`Registration No. 44,541. With respect to this proceeding, I will work closely with
`
`Mr. Blinka.
`
`2. I hold a Bachelor of Arts degree from Dartmouth College. I hold a Juris
`
`Doctor degree from the University Of Virginia School Of Law.
`
`3. I have 27 years of experience as a practicing litigating attorney. My
`
`practice is focused on patent litigation, and I have been counsel in many complex
`
`patent litigation proceedings.
`
`4. In my capacity as a partner with Cooley LLP, I have been intimately
`
`involved with litigation matters in various United States District Courts and Courts
`
`of Appeals, and before the International Trade Commission.
`
`5. I am currently litigation counsel for Horizon in a pending federal district
`
`court action in which Petitioner asserts infringement of U.S. Patent No. 9,220,698,
`
`and I am familiar with the legal subject matter, technical subject matter, and prior
`
`art discussed in Petitioner’s Request for Inter Partes Review of U.S. Patent No.
`
`9,220,698.
`
`6. In my capacity as a partner at Cooley LLP, I have become familiar with
`
`
`
`the legal subject matter, technical subject matter, and prior art involved with
`
`HORIZON'S EXHIBIT 2008
`Page 2 of 5
`
`
`
`U.S. Patent No. 9,220,698.
`
`7. I am therefore qualified to represent the interests of Horizon Pharma
`
`USA, Inc. as an experienced litigation attorney.
`
`8.
`
`In the past three (3) years, I have appeared pro hac vice before the
`
`United States Patent and Trademark Office in two consolidated proceedings, Aker
`
`Biomarine AS v. Neptune Technologies and Bioressources Inc., IPR2014-00003,
`
`and Enzymotec, Ltd. v. Neptune Technologies and Bioressources Inc., IPR2014-
`
`00556. I argued on behalf of the Patent Owner in the oral hearing in those
`
`proceedings. I have also appeared pro hac vice on behalf of the Patent Owner in
`
`Eli Lilly and Company v. The Trustees of the University of Pennsylvania, IPR2016-
`
`00458, and on behalf of the Petitioner in HyperBranch Medical Technology, Inc. v.
`
`Incept LLC, IPR2016-01836.
`
`9. I am a member in good standing of the Virginia State Bar and the D.C.
`
`Bar. I am also admitted to practice before the United States District Court for the
`
`Eastern District of Michigan, the United States District Court for the District of
`
`Colorado, the United States District Court for the Central District of California, the
`
`United States District Court for the Eastern District of Texas, the United States
`
`District Court for the Eastern District of Virginia, the United States District Court
`
`for the District of Columbia, the United States Court of Appeals for the Federal
`
`Circuit, the United States Court of Appeals for the Second Circuit, and the United
`
`States Supreme Court.
`
`
`
`
`
`HORIZON'S EXHIBIT 2008
`Page 3 of 5
`
`
`
`10. I have never been suspended or disbarred from practice before any court
`
`or administrative body.
`
`11. I have never had a court or administrative body deny my application for
`
`admission to practice.
`
`12. I have never been sanctioned or cited for contempt by any court or
`
`administrative body.
`
`13. I have read and will comply with the Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials set forth in Part 42 of 37 C.F.R.
`
`14. I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq., and to disciplinary jurisdiction under 37 C.F.R.
`
`§ 11.19(a).
`
`15. I declare that all statements made herein of my own knowledge are true
`
`and that all statements made on information and belief are believed to be true; and
`
`further that these statements were made with the knowledge that willful, false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code and that such willful false
`
`statements may
`
`jeopardize
`
`the validity of U.S. Patent No. 9,220,698.
`
`
`
`
`
`HORIZON'S EXHIBIT 2008
`Page 4 of 5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`DATED: January 12, 2018
`
`
`Jonathan G. Graves
`
`
`
`
`
`
`HORIZON'S EXHIBIT 2008
`Page 5 of 5
`
`
`
`
`
`
`CERTIFICATE OF SERVICE UNDER 37 C.F.R. § 42.6(e)
`
`I, Thomas A. Blinka, hereby certify that on this 12th day of January, 2018, the
`
`foregoing Declaration Of Jonathan G. Graves In Support Of Motion To Appear
`
`Pro Hac Vice On Behalf Of Patent Owner Horizon Pharma USA, Inc. was served
`
`electronically via email on the following:
`
`
`
`Brandon M. White Perkins Coie LLP
`700 Thirteenth Street, N.W., Suite 600
`Washington, D.C. 20005
`bmwhite@perkinscoie.com
`
`Emily J. Greb Perkins Coie LP
`1 East Main Street, Suite 201
`Madison, WI 53703
`egreb@perkinscoie.com
`EsoNaproxen@perkinscoie.com
`
`Date: January 12, 2018
`
`By: /s/ Thomas A. Blinka
`Thomas A. Blinka
`Reg. No. 44,541
`Counsel for Patent Owner
`
`
`
`
`
`151525346 v2
`
`
`
`
`
`HORIZON'S EXHIBIT 2008
`Page 6 of 5
`
`
`